# OnCo record nrm-823 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nrm-823/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nrm-823" ;
  schema:name "NRM-823"@en ;
  schema:description "NRM-823 is an experimental T cell engager from Normunity, in phase 1 trials for head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma and oesophageal adenocarcinoma and other cancers."@en ;
  schema:url <https://onco.cc/drugs/nrm-823/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://normunity.com/pipeline/>, <https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/>, <https://clinicaltrials.gov/api/v2/studies/NCT07182149>, <https://clinicaltrials.gov/search?intr=NRM-823> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "T cell engager (bispecific)" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/tnbc/> ;
  onco:companies <https://onco.cc/companies/normunity/> ;
  onco:trials <https://onco.cc/trials/nct07182149/> .